ESC 365 - End-of-cancer therapy cardiovascular risk assessment and long-term follow-up.

Open Access

End-of-cancer therapy cardiovascular risk assessment and long-term follow-up.

Session: 2022 ESC Guidelines on cardio-oncology

Topic: Cardio-Oncology

Speaker: Professor T. Suter (Bern, CH)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Thomas Suter

Bern University Hospital, Inselspital, Bern (Switzerland)

19 presentations

5 followers

3 more presentations in this session

Cardiovascular toxicity risk stratification before anticancer therapy.

Speaker: Doctor E. de Azambuja (Brussels, BE)

Prevention and monitoring of cardiovascular complications during cancer therapy.

Speaker: Professor J. Bergler-Klein (Vienna, AT)

Diagnosis and management of acute and subacute CVDs in patients with active cancer.

Speaker: Associate Professor D. Farmakis (Athens, GR)

Access the full session

2022 ESC Guidelines on cardio-oncology

Speakers: Professor T. Suter, Doctor E. de Azambuja, Professor J. Bergler-Klein, Associate Professor D. Farmakis

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources